Zobrazeno 1 - 5
of 5
pro vyhledávání: '"Maaz Ahmed Yusufi"'
Autor:
Muhammad Qudrat Ullah, Muhammad Yasir Anwar, Muhammad Abdullah Yousaf, Mustafa Nadeem Malik, Maaz Ahmed Yusufi, Abdul Rafae, Faiz Anwer, Zunairah Shah, Muhaddis Ejaz Ahmad, Asim Tameez Ud Din, Ahmed Ibrahim
Publikováno v:
Blood. 134:5579-5579
Introduction FDA (Food and Drug Administration) fast track program facilitates the development and accelerated review of new drugs aimed at treating life-threatening conditions and having the potential to address unmet medical needs. FDA fast track d
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::2003d1b401e3bae7ac56b1e3a148c275
https://doi.org/10.1182/blood-2019-123296
https://doi.org/10.1182/blood-2019-123296
Autor:
Hamza Hassan, Ahmad Iftikhar, Midhat Lakhani, Muhammad Abdullah Yousaf, Muhaddis Ejaz Ahmad, Adeela Mushtaq, Irbaz Bin Riaz, Faiz Anwer, Seemal Iftikhar, M. Hasib Sidiqi, Razwana Khanam, Aneeqa Zafar, Maaz Ahmed Yusufi
Publikováno v:
Blood. 134:5556-5556
Introduction Amyloidosis is a rare disease and there are currently no FDA approved therapies for AL amyloidosis. Most of the therapeutic and disease data come from expert guidelines, consensus and retrospective review papers. There is a paucity of da
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::8175458d9ba4de2d6b13f24271d0f073
https://doi.org/10.1182/blood-2019-125148
https://doi.org/10.1182/blood-2019-125148
Autor:
Muhammad Abdullah Yousaf, Saif Ur Rehman, Tariq Iqtidar Sadiq Syed, Muhammad Salman Faisal, Maimoona Khan, Awais Ijaz, Muhaddis Ejaz Ahmad, Asma Waheed, Sravanthi Kotapati, Syed Maaz Abdullah, Syeda Sabeeka Batool, Khadija Zia Zaidi, Sikander Abdullah, Maaz Ahmed Yusufi, Faiz Anwer
Publikováno v:
Blood. 134:5589-5589
Introduction: About 60% newly diagnosed multiple myeloma (NDMM) cases are above age of 60 years. The paucity of studies exclusively targeting management of frail patients has led to persistence of therapeutic uncertainties. With data on more than ten
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::9051db837f3545df167bce7baf2d70e6
https://doi.org/10.1182/blood-2019-128892
https://doi.org/10.1182/blood-2019-128892
Autor:
Muhaddis Ejaz Ahmad, Abdul Rafae, Adeela Mushtaq, Muhammad Abdullah Yousaf, Ahmad Iftikhar, Mustafa Nadeem Malik, Faiz Anwer, Zunairah Shah, Adnan Basheer, Hamza Hassan, Maaz Ahmed Yusufi, Ahmed Ibrahim
Publikováno v:
Blood. 134:5583-5583
Introduction: For more than a decade, bortezomib (V) has become an integral part of initial treatment of AL amyloidosis It is cytotoxic to plasma cells. We report published literature on efficacy and safety of bortezomib based regimens in patients (p
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::3506346adbeb009ca3885e57c60ca918
https://doi.org/10.1182/blood-2019-127190
https://doi.org/10.1182/blood-2019-127190
Autor:
Chaudhry Saad Sohail, Shehroz Aslam, Abdul Rafae, Jemin Aby Jose, Ceren Durer, Mustafa Nadeem Malik, Faisal Mahfooz, Faiz Anwer, Zunairah Shah, Rida Riaz, Muhammad Jahanzeb Khalil, Seren Durer, Maaz Ahmed Yusufi
Publikováno v:
Blood. 132:5659-5659
Introduction: Intracellular signaling cascades including mTOR (mammalian target of rapamycin), MEK (mitogen-activated protein kinase), BCL2 (B-cell lymphoma 2), MET, AKT, and BTK (Bruton's tyrosine kinase) pathways are involved in the growth, prolife
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::596b01d675a15ee28a3931174dee1f89
https://doi.org/10.1182/blood-2018-99-115721
https://doi.org/10.1182/blood-2018-99-115721